{"id":7983,"date":"2026-11-17T05:33:42","date_gmt":"2026-11-17T05:33:42","guid":{"rendered":"https:\/\/autism.fratnow.com\/blog\/?p=7983"},"modified":"2026-11-17T05:36:49","modified_gmt":"2026-11-17T05:36:49","slug":"autism-folate-receptor-autoantibodies-and-mitochondrial-function","status":"publish","type":"post","link":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/","title":{"rendered":"Autism, Folate Receptor Autoantibodies and Mitochondrial Function"},"content":{"rendered":"<p>[vc_row el_class=&#8221;blog-inner-content-row&#8221;][vc_column el_class=&#8221;blog-main-content&#8221;][vc_single_image image=&#8221;7984&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221; el_class=&#8221;blog-hero-img&#8221;][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<p><a href=\"https:\/\/autism.fratnow.com\/blog\/a-comprehensive-introduction-to-autism-spectrum-disorder\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Autism spectrum disorder (ASD)<\/strong><\/a> is famously heterogeneous\u2014a single label that encompasses a wide array of biological and clinical realities. For years, this heterogeneity has frustrated efforts to find broadly effective treatments, as interventions that show promise in one group of children may show little benefit in another. A growing body of research, however, is moving toward a biomarker-based approach, identifying distinct biological subtypes within the autism spectrum. One of the most compelling and clinically actionable of these is the\u00a0<a href=\"https:\/\/autism.fratnow.com\/blog\/folate-receptor-autoantibodies-in-families-with-autistic-individuals\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>FRAA (folate receptor autoantibodies)<\/strong><\/a><strong> &#8211; positive, mitochondrial-dysfunction phenotype<\/strong>. This subtype is defined by a specific, measurable biological signature (folate receptor autoantibodies detected by the <strong>FRAT<sup>\u00ae<\/sup><\/strong> test) that not only deepens our understanding of autism&#8217;s underlying biology but also points toward a targeted, and in some cases remarkably effective, treatment.<\/p>\n<p>[\/vc_column_text][vc_row_inner el_id=&#8221;blog-scroll-point-1&#8243; el_class=&#8221;blog-section-row&#8221;][vc_column_inner][vc_custom_heading text=&#8221;The Biology: A Tale of Two Transporters&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;the-biology-a-tale-of-two-transporters&#8221;][vc_column_text single_style=&#8221;&#8221;]To understand this phenotype, we must first look at the intersection of two critical systems: folate transport into the brain and cellular energy production.[\/vc_column_text][vc_custom_heading text=&#8221;The Folate Pathway and FRAAs&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;the-folate-pathway-and-fraas&#8221;][vc_column_text single_style=&#8221;&#8221;]<a href=\"https:\/\/autism.fratnow.com\/blog\/importance-of-vitamin-b9-folate-for-better-brain-development-in-fetuses\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Folate (vitamin B9)<\/strong><\/a> is essential for brain development and function. A specific form,\u00a0<strong>5-methyltetrahydrofolate (5-MTHF)<\/strong>, is the primary active folate in the central nervous system. To get from the blood into the brain, 5-MTHF must pass the blood-brain barrier via a specialized transport system. The key transporter is the\u00a0<strong>folate receptor alpha (FR\u03b1)<\/strong>, which pumps folate into the brain through an\u00a0<strong>ATP-dependent<\/strong>\u00a0(energy-requiring) process. They key piece here is \u201cenergy\u201d.[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]When this transport system fails, a condition called\u00a0<a href=\"https:\/\/autism.fratnow.com\/blog\/cerebral-folate-deficiency-an-overview\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>cerebral folate deficiency<\/strong><\/a> <strong>syndrome (CFDS)<\/strong>\u00a0occurs\u2014low folate in the brain despite normal levels in the blood. One major cause of CFDS is the presence of\u00a0<strong>folate receptor alpha autoantibodies (FRAAs)<\/strong>. These are antibodies that mistakenly target and block or bind to the FR\u03b1, impairing its ability to transport folate into the brain. Studies have found that a striking\u00a0~<strong>71% of children with ASD are positive for FRAAs<\/strong>, compared to a much lower rate in the general population, making them\u00a0~<strong>19 times more likely<\/strong>\u00a0to have these autoantibodies.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;blog-scroll-point-2&#8243; el_class=&#8221;blog-section-row&#8221;][vc_column_inner][vc_custom_heading text=&#8221;The Mitochondrial Connection&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;the-mitochondrial-connection&#8221;][vc_column_text single_style=&#8221;&#8221;]This is where mitochondria\u2014the cell&#8217;s power plants\u2014enter the story. Because FR\u03b1-mediated folate transport is\u00a0<strong>ATP-dependent<\/strong>, mitochondria must supply the energy for this process to work. Mitochondrial dysfunction is well-documented in a substantial subset of individuals with ASD, characterized by reduced ATP production, increased oxidative stress, and impaired mitochondrial dynamics. When mitochondria are not functioning optimally, the energy supply for the FR\u03b1 transporter can falter, leading to CFDS\u00a0<strong>even in the absence of FRAAs<\/strong>. This creates a dual-hit scenario: a child may have CFDS driven by autoimmune blockade of the transporter (FRAAs), by energy failure (mitochondrial dysfunction), or, most commonly, by a combination of both.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;blog-scroll-point-3&#8243; el_class=&#8221;blog-section-row&#8221;][vc_column_inner][vc_custom_heading text=&#8221;The Phenotype: A Treatable Subtype?&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;the-phenotype-a-treatable-subtype&#8221;][vc_column_text single_style=&#8221;&#8221;]The clinical picture of children with this combined FRAA-positive and mitochondrial-dysfunction profile is not yet fully delineated, but research is beginning to reveal a distinct pattern of features and, crucially, a specific treatment response.[\/vc_column_text][vc_custom_heading text=&#8221;Clinical Features&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;clinical-features&#8221;][vc_column_text single_style=&#8221;&#8221;]Children with CFDS and FRAAs can present with a range of neurological and developmental symptoms. Core autistic features are prominent, but the phenotype often extends to include:[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<ul>\n<li><strong>Language and Communication Deficits<\/strong>: This is a particularly salient feature. Many children in this subgroup exhibit significant language delay, and verbal communication is a primary outcome that improves with targeted treatment.<\/li>\n<li><strong>Neurological Signs<\/strong>: Seizures, movement disorders (such as ataxia or dyskinesias), and pyramidal tract signs (like spasticity) are frequently reported in CFD.<\/li>\n<li><strong>Developmental Regression<\/strong>: Some children may experience a loss of previously acquired skills, particularly in the context of the broader CFD syndrome.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]Furthermore, research suggests that the\u00a0<em>type<\/em>\u00a0of FRAA matters. Children positive for\u00a0<strong>blocking FRAAs<\/strong>\u00a0appear to have a somewhat more favorable profile, with better communication scores on adaptive behavior scales compared to those with\u00a0<strong>binding FRAAs<\/strong>.[\/vc_column_text][vc_custom_heading text=&#8221;The \u201cOff-Label\u201d Use of Leucovorin (Folinic Acid)&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;the-off-label-use-of-leucovorin-folinic-acid&#8221;][vc_column_text single_style=&#8221;&#8221;]The most significant implication of identifying this subtype is its potential for treatment. The standard treatment, <em>although not approved by the FDA and used \u201coff label\u201d<\/em> for CFDS is\u00a0<strong>leucovorin (folinic acid)<\/strong>, a reduced form of folate. Unlike folic acid, leucovorin can bypass the blocked FR\u03b1 transporter and enter the brain through an alternative route, the reduced folate carrier (RFC).[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]Clinical trials have shown that leucovorin can produce meaningful improvements in children with ASD and CFD, but the benefits are\u00a0<strong>most pronounced in the FRAA-positive subgroup<\/strong>:[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]<\/p>\n<ul>\n<li>A meta-analysis found that in individuals with ASD and CFD, leucovorin led to improvements in overall symptoms (67%), irritability (58%), and even neurological signs like ataxia (88%).<\/li>\n<li>Placebo-controlled trials have demonstrated significant gains in\u00a0<strong>verbal communication<\/strong>\u00a0with medium-to-large effect sizes, with FRAA-positive children being more likely to respond.<\/li>\n<li>The treatment is generally well-tolerated, with side effects that are typically mild and transient, such as agitation or headaches.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]This stands in stark contrast to the broader, often disappointing results when leucovorin is tested in unselected autism populations. The difference is the\u00a0<strong>&#8220;dilution effect\u201d:<\/strong> in a heterogeneous group, the significant gains in the treatable subgroup are statistically washed out by the non-responders. This highlights a critical lesson:\u00a0<strong>targeting the right biological subtype is essential for demonstrating treatment efficacy.<\/strong>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;blog-scroll-point-4&#8243; el_class=&#8221;blog-section-row&#8221;][vc_column_inner][vc_custom_heading text=&#8221;From Subtype to Standard of Care&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;from-subtype-to-standard-of-care&#8221;][vc_column_text single_style=&#8221;&#8221;]The FRAA-positive, mitochondrial-dysfunction phenotype represents a paradigm shift in how we think about autism. It moves the conversation from a purely behavioral diagnosis to one that incorporates measurable, treatable biological markers. However, significant work remains. The field needs larger, biomarker-stratified clinical trials to confirm these findings and to standardize protocols for FRAA testing and leucovorin dosing. There is also a need to better understand the natural history of this subtype and the long-term outcomes of early intervention.[\/vc_column_text][vc_column_text single_style=&#8221;&#8221;]For now, this research offers a message of both hope and caution. It provides a clear, biologically plausible explanation for why some children with autism respond dramatically to a simple vitamin derivative while others do not. It also underscores that autism is not one condition, but many\u2014and that the future of effective treatment lies in looking beneath the behavioral surface to the underlying biology.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;blog-scroll-point-5&#8243; el_class=&#8221;blog-references-row&#8221;][vc_column_inner][vc_custom_heading text=&#8221;References&#8221; use_theme_fonts=&#8221;yes&#8221; el_id=&#8221;references&#8221;][vc_column_text single_style=&#8221;&#8221; el_class=&#8221;blog-ref-list&#8221;]<\/p>\n<ol>\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8622150\/?report=classic#1\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8622150\/?report=classic#1<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27752075\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/pubmed.ncbi.nlm.nih.gov\/27752075\/<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32387472\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/pubmed.ncbi.nlm.nih.gov\/32387472\/<\/a><\/li>\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4783401\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4783401\/<\/a><\/li>\n<li><a href=\"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2479\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2479<\/a><\/li>\n<\/ol>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.<\/p>\n","protected":false},"author":4,"featured_media":7984,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[61],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Autism, Folate Receptor Autoantibodies and Mitochondrial Function What is the Connection?<\/title>\n<meta name=\"description\" content=\"Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autism, Folate Receptor Autoantibodies and Mitochondrial Function What is the Connection?\" \/>\n<meta property=\"og:description\" content=\"Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/\" \/>\n<meta property=\"og:site_name\" content=\"fratnow.com\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/autismfrat\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T05:33:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-17T05:36:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/11\/autism-folate-receptor-autoantibodies-and-mitochondrial-function-what-is-the-connection-blog-listing-image.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"730\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Steve Tsetsekos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Autism, Folate Receptor Autoantibodies and Mitochondrial Function What is the Connection?\" \/>\n<meta name=\"twitter:description\" content=\"Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/11\/autism-folate-receptor-autoantibodies-and-mitochondrial-function-what-is-the-connection-blog-listing-image.webp\" \/>\n<meta name=\"twitter:creator\" content=\"@AutismFrat\" \/>\n<meta name=\"twitter:site\" content=\"@AutismFrat\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Tsetsekos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autism, Folate Receptor Autoantibodies and Mitochondrial Function What is the Connection?","description":"Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/","og_locale":"en_US","og_type":"article","og_title":"Autism, Folate Receptor Autoantibodies and Mitochondrial Function What is the Connection?","og_description":"Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.","og_url":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/","og_site_name":"fratnow.com","article_publisher":"https:\/\/www.facebook.com\/autismfrat","article_published_time":"2026-11-17T05:33:42+00:00","article_modified_time":"2026-11-17T05:36:49+00:00","og_image":[{"width":730,"height":400,"url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/11\/autism-folate-receptor-autoantibodies-and-mitochondrial-function-what-is-the-connection-blog-listing-image.webp","type":"image\/webp"}],"author":"Steve Tsetsekos","twitter_card":"summary_large_image","twitter_title":"Autism, Folate Receptor Autoantibodies and Mitochondrial Function What is the Connection?","twitter_description":"Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.","twitter_image":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2026\/11\/autism-folate-receptor-autoantibodies-and-mitochondrial-function-what-is-the-connection-blog-listing-image.webp","twitter_creator":"@AutismFrat","twitter_site":"@AutismFrat","twitter_misc":{"Written by":"Steve Tsetsekos","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","BlogPosting"],"@id":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/#article","isPartOf":{"@id":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/"},"author":{"name":"Steve Tsetsekos","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/d5e4020455f25cb3768f5eb9ad5e9f1c"},"headline":"Autism, Folate Receptor Autoantibodies and Mitochondrial Function","datePublished":"2026-11-17T05:33:42+00:00","dateModified":"2026-11-17T05:36:49+00:00","mainEntityOfPage":{"@id":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/"},"wordCount":1379,"commentCount":0,"publisher":{"@id":"https:\/\/autism.fratnow.com\/blog\/#organization"},"articleSection":["Autism"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/","url":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/","name":"Autism, Folate Receptor Autoantibodies and Mitochondrial Function What is the Connection?","isPartOf":{"@id":"https:\/\/autism.fratnow.com\/blog\/#website"},"datePublished":"2026-11-17T05:33:42+00:00","dateModified":"2026-11-17T05:36:49+00:00","description":"Explore the connection between autism, folate receptor autoantibodies (FRAAs), mitochondrial dysfunction, cerebral folate deficiency, and leucovorin treatment.","breadcrumb":{"@id":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/autism.fratnow.com\/blog\/autism-folate-receptor-autoantibodies-and-mitochondrial-function\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/autism.fratnow.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Autism, Folate Receptor Autoantibodies and Mitochondrial Function"}]},{"@type":"WebSite","@id":"https:\/\/autism.fratnow.com\/blog\/#website","url":"https:\/\/autism.fratnow.com\/blog\/","name":"fratnow.com","description":"","publisher":{"@id":"https:\/\/autism.fratnow.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/autism.fratnow.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/autism.fratnow.com\/blog\/#organization","name":"fratnow.com","url":"https:\/\/autism.fratnow.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/08\/logo.png","contentUrl":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/08\/logo.png","width":194,"height":66,"caption":"fratnow.com"},"image":{"@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/autismfrat","https:\/\/twitter.com\/AutismFrat","https:\/\/www.linkedin.com\/company\/88011685\/admin\/","https:\/\/www.instagram.com\/fratautism\/"]},{"@type":"Person","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/d5e4020455f25cb3768f5eb9ad5e9f1c","name":"Steve Tsetsekos","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/autism.fratnow.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/09\/e6cec733-36d3-42ae-a0a7-986995164499_medium.jpg","contentUrl":"https:\/\/autism.fratnow.com\/blog\/wp-content\/uploads\/2023\/09\/e6cec733-36d3-42ae-a0a7-986995164499_medium.jpg","caption":"Steve Tsetsekos"},"sameAs":["https:\/\/autism.fratnow.com\/blog\/"],"url":"https:\/\/autism.fratnow.com\/blog\/author\/steve-tsetsekos\/"}]}},"_links":{"self":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7983"}],"collection":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/comments?post=7983"}],"version-history":[{"count":4,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7983\/revisions"}],"predecessor-version":[{"id":7988,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/posts\/7983\/revisions\/7988"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/media\/7984"}],"wp:attachment":[{"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/media?parent=7983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/categories?post=7983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/autism.fratnow.com\/blog\/wp-json\/wp\/v2\/tags?post=7983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}